336 related articles for article (PubMed ID: 2186058)
1. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Gettys TW; Taylor IL; Rushakoff RJ; Williams VC; Coker LD
J Clin Endocrinol Metab; 1990 May; 70(5):1312-8. PubMed ID: 2186058
[TBL] [Abstract][Full Text] [Related]
2. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
3. Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.
Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Coker LD; Turnbull TA; Morita ET
J Clin Invest; 1989 Oct; 84(4):1220-5. PubMed ID: 2794058
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329.
Cantor P; Olsen O; Gertz BJ; Gjorup I; Worning H
Scand J Gastroenterol; 1991 Jun; 26(6):627-37. PubMed ID: 1713709
[TBL] [Abstract][Full Text] [Related]
5. Physiological role of cholecystokinin in meal-induced insulin secretion in conscious rats. Studies with L 364718, a specific inhibitor of CCK-receptor binding.
Rossetti L; Shulman GI; Zawalich WS
Diabetes; 1987 Oct; 36(10):1212-5. PubMed ID: 3308589
[TBL] [Abstract][Full Text] [Related]
6. The effect of the cholecystokinin receptor antagonist MK-329 on meal-stimulated pancreaticobiliary output in humans.
Cantor P; Mortensen PE; Myhre J; Gjorup I; Worning H; Stahl E; Survill TT
Gastroenterology; 1992 May; 102(5):1742-51. PubMed ID: 1568584
[TBL] [Abstract][Full Text] [Related]
7. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
[TBL] [Abstract][Full Text] [Related]
8. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man.
Ahrén B; Pettersson M; Uvnäs-Moberg K; Gutniak M; Efendic S
Diabetes Res Clin Pract; 1991 Sep; 13(3):153-61. PubMed ID: 1683622
[TBL] [Abstract][Full Text] [Related]
9. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans.
Liddle RA; Rushakoff RJ; Morita ET; Beccaria L; Carter JD; Goldfine ID
J Clin Invest; 1988 Jun; 81(6):1675-81. PubMed ID: 3290250
[TBL] [Abstract][Full Text] [Related]
10. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice.
Karlsson S; Ahrén B
Acta Physiol Scand; 1989 Mar; 135(3):271-8. PubMed ID: 2648765
[TBL] [Abstract][Full Text] [Related]
11. Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice.
Ahrén B; Gingerich RL; Havel PJ
Regul Pept; 1995 Nov; 59(3):297-302. PubMed ID: 8577934
[TBL] [Abstract][Full Text] [Related]
12. Effects of non-peptidal CCK receptor antagonist (L-364,718) on pancreatic responses to cholecystokinin, gastrin, bombesin, and meat feeding in dogs.
Konturek SJ; Tasler J; Konturek JW; Cieszkowski M; Szewczyk K; Hładij M; Anderson PS
Gut; 1989 Jan; 30(1):110-7. PubMed ID: 2920915
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
14. Effect of CCK on insulin, glucagon, and pancreatic polypeptide levels in humans.
Schmid R; Schusdziarra V; Schulte-Frohlinde E; Maier V; Classen M
Pancreas; 1989; 4(6):653-61. PubMed ID: 2682604
[TBL] [Abstract][Full Text] [Related]
15. Cholecystokinin is not a major determinant for the changes in beta-cell function seen after pancreatico-biliary diversion in rats.
Gasslander T; Lilja I; Smeds S; Lundquist I; Ihse I
Diabetes Res; 1991 Nov; 18(3):135-42. PubMed ID: 1841824
[TBL] [Abstract][Full Text] [Related]
16. Effect of L-364,718 on pancreatic endocrine function following partial pancreatectomy.
Presti ME; Niehoff ML; Burton FR; Solomon H; Garvin PJ
J Surg Res; 1996 Aug; 64(2):170-5. PubMed ID: 8812629
[TBL] [Abstract][Full Text] [Related]
17. L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.
Hosotani R; Chowdhury P; Rayford PL
Dig Dis Sci; 1989 Mar; 34(3):462-7. PubMed ID: 2646088
[TBL] [Abstract][Full Text] [Related]
18. Effects of CCK on pancreatic function and morphology.
Niederau C; Lüthen R; Heintges T
Ann N Y Acad Sci; 1994 Mar; 713():180-98. PubMed ID: 8185159
[TBL] [Abstract][Full Text] [Related]
19. Cholecystokinin in the regulation of gastric acid and endocrine pancreatic secretion in humans.
Konturek JW; Stoll R; Gutwinska-Konturek M; Konturek SJ; Domschke W
Scand J Gastroenterol; 1993 May; 28(5):401-7. PubMed ID: 8511500
[TBL] [Abstract][Full Text] [Related]
20. Circulating amino acids and pancreatic endocrine function after ingestion of a protein-rich meal in obese subjects.
Schmid R; Schusdziarra V; Schulte-Frohlinde E; Maier V; Classen M
J Clin Endocrinol Metab; 1989 Jun; 68(6):1106-10. PubMed ID: 2656733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
